Study on brain targeting of raltitrexed following intranasal administration in rats

被引:60
作者
Wang, DX [1 ]
Gao, YL [1 ]
Yun, LH [1 ]
机构
[1] Beijing Inst Pharmacol & Toxicol, Beijing 10085, Peoples R China
关键词
raltitrexed; intranasal administration; blood-brain barrier; brain targeting;
D O I
10.1007/s00280-005-0018-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: To investigate the levels of raltitrexed (RTX) in blood and different brain tissues in rats and to find out whether there is any direct drug transport from nasal cavity to brain tissues following intranasal (i.n.) administration. Methods: Raltitrexed was administered to male Sprague-Dawley rats either intranasally or intravenously. Drug concentrations in blood and brain tissues were determined at different times post dosing. Results: The plasma levels achieved after i.n. administration were significantly lower than those following intravenous (i.v.) administration (P<0.05) before 120 min; but were significantly higher (P < 0.05) after 120 min. Following i.n. administration, RTX concentrations in different brain tissues were constantly detected for quite a long time and differed significantly from each other, the rank order being C-OB > C-OT > C-CR > C-CL. On the contrary, RTX appeared only at the initial two or three time points in different brain regions after i.v. injection, and the concentrations were similar. AUC values in four brain regions by the nasal route were 54- to 121-fold compared with the i.v. route, the drug targeting index (DTI) values of nasal route were 71-158 for different brain regions, and about 99% of RTX content within 360 min in the brain were transported via the olfactory pathway. Conclusions: These results showed that antineoplastic RTX could be directly transported into the brain via the olfactory pathway in rats.
引用
收藏
页码:97 / 104
页数:8
相关论文
共 34 条
[1]
A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug [J].
Bagger, M ;
Bechgaard, E .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 269 (02) :311-322
[2]
Effects of physicochemical properties and other factors on systemic nasal drug delivery [J].
Behl, CR ;
Pimplaskar, HK ;
Sileno, AP ;
deMeireles, J ;
Romeo, VD .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 29 (1-2) :89-116
[3]
Chow HHS, 1999, J PHARM SCI, V88, P754
[4]
Phase I trial of ZDI694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors [J].
Clarke, SJ ;
Hanwell, J ;
deBeer, M ;
Planting, A ;
VerweiJ, J ;
Walker, M ;
Smith, R ;
Jackman, AL ;
Hughes, LR ;
Harrap, KR ;
Kennealey, GT ;
Judson, IR .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) :1495-1503
[5]
Clinical and preclinical pharmacokinetics of raltitrexed [J].
Clarke, SJ ;
Beale, PJ ;
Rivory, LP .
CLINICAL PHARMACOKINETICS, 2000, 39 (06) :429-443
[6]
New systems for delivery of drugs to the brain in neurological disease [J].
Cornford, EM ;
Cornford, ME .
LANCET NEUROLOGY, 2002, 1 (05) :306-315
[7]
'Tomudex' (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia [J].
Cunningham, D ;
Zalcberg, JR ;
Rath, U ;
Olver, I ;
VanCutsem, E ;
Svensson, C ;
Seitz, JF ;
Harper, P ;
Kerr, D ;
PerezManga, G ;
Azab, M ;
Seymour, L ;
Lowery, K ;
Ackland, SP ;
Basser, RL ;
Clarke, SJ ;
Goldstein, D ;
Green, MD ;
Grygiel, JJ ;
McKendrick, JJ ;
Millward, MJ ;
Olver, IN ;
Tattersall, MHN ;
Thomson, DB ;
Jakesz, R ;
Buset, M ;
Tueni, EA ;
VanCutsem, EJD ;
Bauer, J ;
Beska, F ;
Adenis, A ;
Brunet, R ;
Francois, E ;
Paillot, B ;
Rougier, P ;
Fink, UFW ;
Knuth, KRA ;
Koenig, HJ ;
Bohme, MWJ ;
Wander, HE ;
Amadori, D ;
Frassineti, L ;
Cocconi, G ;
Passalacqua, R ;
Frigerio, F ;
Barni, S ;
Luporini, G ;
Labianca, R ;
Marini, G ;
Zaniboni, A .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (12) :1945-1954
[8]
Levels of dopamine in blood and brain following nasal administration to rats [J].
Dahlin, M ;
Jansson, B ;
Björk, E .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 14 (01) :75-80
[9]
Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer's disease to rats [J].
Dahlin, M ;
Björk, E .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 212 (02) :267-274
[10]
Nasal absorption of (S)-UH-301 and its transport into the cerebrospinal fluid of rats [J].
Dahlin, M ;
Björk, E .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 195 (1-2) :197-205